Appili Therapeutics submits CTA with Health Canada to sponsor trial of favipiravir as preventative measure against Covid-19

This article was originally published here

Favipiravir is approved in Japan as the anti-influenza drug Avigan. With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care

The post Appili Therapeutics submits CTA with Health Canada to sponsor trial of favipiravir as preventative measure against Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply